Amgen posts flat Q4 revenue $6.8B, GAAP EPS down 11%; FTC extends HSR review for Horizon deal

AMGEN INC

2022-FY EPS reported $12.11 revenue$26,323,000,000

GAAP EPS $3.00 (down 11% YoY); non-GAAP EPS $4.09 (down 7% YoY).
Total revenue $6.8B unchanged; product sales +4% with 10% volume growth.
Full year 2022 revenue $26.3B (+1%), GAAP EPS $12.11, non-GAAP EPS $17.69.
FTC issued Second Request for Horizon acquisition, extending HSR waiting period 30 days after compliance.
2023 guidance provided excluding Horizon; free cash flow $8.8B for full year 2022.

item 1.01 item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AMGEN INC reported the three months ended December 31, 2022 results: revenue $6.8 billion, EPS $3.00.

Period: the three months ended December 31, 2022
Revenue: $6.8 billion
EPS: $3.00
Result: reported results

Exact text from the filing

For the fourth quarter, total revenues were $6.8 billion, largely unchanged from Q4 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AMGEN INC reported the year ended December 31, 2022 results: revenue $26.3 billion, EPS $12.11.

Period: the year ended December 31, 2022
Revenue: $26.3 billion
EPS: $12.11
Result: reported results

Exact text from the filing

For the full year, total revenues increased 1% to $26.3 billion

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

AMGEN INC updated its 2023 guidance (initiated).

Period: 2023
Guidance: initiated
Result: guidance update

Exact text from the filing

AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

AMGEN INC filing history →

Source: SEC EDGAR

accession 0000318154-23-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.